Once reserved for complex diabetes cases, injectable GLP‑1 drugs like Ozempic have broken into the mainstream as weight‑loss tools. New research now suggests that, for a small number of people, these hugely popular treatments could be linked to a rare kind of sudden and sometimes permanent vision loss.
From diabetes breakthrough to celebrity slimming jab
Só-called “skinny jabs” were never designed as beauty products. Semaglutide, the active ingredient in Ozempic, Wegovy and the tablet Rybelsus, was originally developed to help people with type 2 diabetes manage blood sugar.
The drug mimics GLP‑1, a gut hormone that boosts insulin release, slows stomach emptying and sends stronger “I’m full” signals to the brain. Many patients see sharp weight loss, lower blood pressure and improved blood sugar control.
Once data showed that higher-dose versions could help people with obesity shed significant weight, demand exploded. Social media hyped the injections. Waiting lists grew. Supplies ran short in several countries.
Behind the weight‑loss buzz, eye specialists have flagged a potential link between semaglutide and a rare but serious optic nerve condition.
The issue is not about the common side effects people already know – nausea, diarrhoea, constipation. The concern now centres on a condition sometimes nicknamed a “stroke of the eye”.
What is this rare eye condition doctors are worried about?
The main fear highlighted in recent work is a disorder called non‑arteritic anterior ischaemic optic neuropathy, or NAION.
NAION happens when blood flow to the optic nerve suddenly drops. The nerve tissue becomes starved of oxygen. That damage can occur very quickly.
Typical features of NAION include:
➡️ Lara Croft is back with two new Tomb Raider games, but something major has clearly changed
➡️ India Builds A National Tank Engine Industry France Abandoned Decades Ago
➡️ Gray Hair May Be Reversible, Study Says
- Sudden, usually painless loss of vision in one eye
- A dark patch or shadow in part of the visual field
- Blurring on waking, sometimes noticed first thing in the morning
- Vision often not fully recovering, even after treatment stops
NAION is rare in the general population – only a few cases per 100,000 people each year. Yet its impact is life‑changing when it happens, and it tends to strike people who already have vascular risk factors such as diabetes, high blood pressure or sleep apnoea.
What the new studies on Ozempic and vision actually found
US hospital data points to a higher NAION rate
One key study came from Massachusetts Eye and Ear, a major eye hospital in Boston, tracking patients between 2017 and 2023. Researchers looked at people with diabetes or obesity, comparing those treated with semaglutide against similar patients not using the drug.
They reported that NAION appeared more often in those on semaglutide. According to the analysis, the risk was about:
- 4 times higher among patients with diabetes using semaglutide
- More than 7 times higher among patients with obesity on the drug
The study, published in JAMA Ophthalmology in 2024, included over 16,000 patients, which gave it statistical weight. Yet it was observational, meaning it cannot prove that semaglutide directly caused NAION. The people on semaglutide might already have had higher baseline risks.
The US data do not prove causation, but they raised a strong enough signal for regulators and researchers to take notice.
Swedish‑Australian research hints at a small but real increase
A second piece of evidence came from a collaboration between the Karolinska Institutet in Sweden and the University of Melbourne. Their analysis also saw a slightly higher rate of NAION in people exposed to GLP‑1 drugs, including semaglutide, compared with control groups.
The absolute numbers were tiny: around 0.04% of patients developed NAION in the cohort they followed. That means the vast majority of users never encountered this complication. Yet when you scale these percentages to millions of prescriptions worldwide, even rare risks start to matter.
The picture is further complicated because diabetes itself increases NAION risk. A previous meta‑analysis published in 2013 found that people with diabetes had about a 64% higher risk of NAION than non‑diabetics.
This makes it challenging to tease apart what portion of the risk comes from the disease, and what might be added – if anything – by rapid shifts in blood sugar or body weight triggered by drugs such as semaglutide.
European regulators move semaglutide’s eye risk up the label
Against this background, European regulators have acted. In June 2025, the European Medicines Agency updated semaglutide’s safety information, listing NAION as a “very rare” side effect.
The EMA now advises patients and doctors to stop semaglutide immediately if sudden changes in vision appear.
This does not mean the drug is considered unsafe overall. Regulatory bodies routinely adjust product labels as new evidence emerges. Still, the move signals that health authorities consider the potential link serious enough to warrant clear, practical guidance.
Weighing benefits against a rare but serious harm
Doctors are facing a delicate calculation. Semaglutide and related GLP‑1 drugs cut the risk of heart attacks, strokes and premature death in people with type 2 diabetes and obesity. They can help patients lose 10–15% of their body weight, transform blood sugar control and ease the burden on joints and organs.
On the other hand, NAION can irreversibly damage sight. So who should be most cautious?
Who might face higher eye risk?
Experts currently point to several groups where extra vigilance makes sense:
- People with sleep apnoea, which can disturb oxygen supply at night
- Those with long‑standing diabetes or poorly controlled blood pressure
- Patients with a history of eye disease or previous NAION in one eye
- Individuals with a “crowded” optic disc – a structural variant seen on eye scans
In these cases, many specialists recommend closer ophthalmology follow‑up once GLP‑1 treatment begins, rather than rejecting the medication outright. For some, alternative strategies or lower targets for weight loss may be considered.
What patients on Ozempic and similar drugs should watch for
People already using semaglutide do not need to panic or immediately stop their injections on their own. Abruptly dropping a successful diabetes or obesity therapy can carry its own dangers.
Instead, eye doctors suggest a few practical steps:
- Report any sudden vision change, blurring or dark patches straight away
- Mention GLP‑1 treatment at every eye appointment
- Keep blood pressure, cholesterol and sleep apnoea under tight control
- Avoid missing scheduled follow‑ups, especially in the first year of treatment
The key signal to act on is any rapid, unexplained change in sight – particularly in one eye and without pain.
Where a doctor suspects NAION, guidelines now lean toward stopping the GLP‑1 drug and reassessing the overall treatment plan.
What scientists still do not fully understand
The biological link between GLP‑1 drugs and optic nerve damage remains unclear. Several theories are on the table.
One idea is that rapid swings in blood sugar or blood pressure could briefly disturb the tiny vessels feeding the optic nerve. Another is that GLP‑1 receptors on blood vessels might subtly alter blood flow in sensitive tissues. Sudden, large drops in weight can also shift fluid balance within the body.
To clarify these questions, long‑term studies are underway. One international project is following around 1,500 patients on semaglutide over five years, tracking detailed retinal scans, visual fields and nerve structure. Findings from this kind of work are expected to provide a clearer risk profile.
Understanding the jargon: GLP‑1, NAION and crowded discs
For patients caught in the crossfire of headlines, the medical language can be baffling. Three terms matter most:
| Term | What it means |
|---|---|
| GLP‑1 agonist | A drug that mimics the gut hormone GLP‑1 to lower blood sugar and reduce appetite. |
| NAION | A sudden loss of blood flow to the front part of the optic nerve, causing vision loss. |
| Crowded optic disc | A tight anatomical configuration of the optic nerve head, which may leave less “reserve” if blood flow drops. |
Patients with a crowded disc often do not notice anything in daily life. The feature is usually found only when an eye specialist looks carefully at the back of the eye through a dilated pupil or with imaging tools.
Real‑life scenarios: when does stopping the drug make sense?
Imagine a 58‑year‑old with type 2 diabetes, obesity and sleep apnoea who starts semaglutide. He loses 12% of his body weight, blood sugar improves, and his cardiologist is pleased. Six months later, he wakes with a dark shadow over part of the vision in one eye, without pain.
In that situation, an urgent eye assessment is needed. If NAION is diagnosed, most specialists would recommend halting semaglutide, addressing other risk factors aggressively and monitoring the remaining eye closely. The cardiometabolic benefits are acknowledged, but protecting the remaining vision takes priority.
Contrast that with a 40‑year‑old with severe obesity but no diabetes, normal blood pressure and no eye problems. She starts Wegovy under supervision, tolerates the drug well, and shows no visual symptoms. For her, the balance may clearly favour continuing therapy, while staying informed about early warning signs.
Balancing weight, heart health and sight over the long term
For many people, obesity and uncontrolled diabetes damage tiny blood vessels in the eyes, kidneys and brain for years. GLP‑1 drugs can reverse part of that trajectory, which is why specialists remain broadly supportive of their use.
The emerging signal on NAION does not cancel those gains. It adds another layer of nuance. Eye health now joins heart attack and stroke prevention, cancer risk, liver disease, mental health and quality of life on the long list of factors to weigh up when starting – or staying on – a powerful weight‑loss injection.
Patients considering Ozempic or Wegovy can use this new evidence as a prompt for more detailed conversations. Asking about eye checks, reporting symptoms quickly and sharing full medical histories with both endocrinologists and ophthalmologists helps keep the focus on what really matters: losing weight and controlling diabetes without sacrificing long‑term vision.
Originally posted 2026-02-13 08:05:13.